BridgeBio Oncology director receives 52,269 stock options; vesting tied to S-8

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a Form 4 filing showing that Praveen P. Tipirneni, a company director, was granted a stock option on 08/26/2025. The option is a right to buy 52,269 shares of common stock at an exercise price of $9.59 per share. The option award is held directly by the reporting person and is recorded as acquired (Transaction Code A). The award includes a vesting schedule tied to an August 11, 2025 vesting commencement date where a fractional portion vests upon effectiveness of a Form S-8 registration statement and then vests monthly over 48 months until fully vested on the fourth anniversary, subject to continuous service.

The filing is signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.

Positive

• Director received equity-based compensation (52,269 stock options), which aligns leadership incentives with shareholders
• Clear vesting schedule tied to an S-8 filing and monthly vesting over 48 months provides transparency on future vesting timing
• Exercise price disclosed at $9.59 per share, allowing investors to model potential future dilution or insider participation

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received a sizable option grant (52,269 options) with multi-year vesting tied to an S-8 registration.

This Form 4 documents an equity-based compensation action rather than a cash transaction or sale. The award provides long-term equity exposure through an option exercisable at $9.59 per share and vests over up to four years, subject to an initial vesting contingent on an effective Form S-8. For investors, the item is routine: it aligns the director's incentives with shareholders but does not itself change company fundamentals or outstanding cash flows. The filing supplies exact grant size, exercise price, vesting commencement date (08/11/2025), and signature date (08/28/2025), enabling precise tracking of potential future dilution once options vest and are exercised.

Corporate Governance Expert

TL;DR: Governance action: a director equity grant with conditional vesting tied to a registration statement.

The grant follows common governance practices by conditioning initial vesting on an S-8 registration statement becoming effective, ensuring compliance for resale and issuance. The monthly vesting thereafter over 48 months is a standard service-based schedule. The report identifies the reporting person as a director and shows direct ownership form. The filing is properly executed by an attorney-in-fact and dated 08/28/2025, satisfying disclosure formalities required under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tipirneni Praveen P.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		52,269		(1)	08/25/2035	Common Stock	52,269	$0	52,269	D

Explanation of Responses:

1. A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 ("Vesting Commencement Date") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the "S-8 Filing Date") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan,Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Praveen P. Tipirneni report on Form 4 for BBOT?

The Form 4 reports an acquisition (Transaction Code A) of a stock option to buy 52,269 shares of BBOT common stock at an exercise price of $9.59 per share on 08/26/2025.

When does the option vest according to the Form 4?

Vesting begins from the Vesting Commencement Date of 08/11/2025; a fraction vests when a Form S-8 registration is filed and effective, then 1/48th of the underlying shares vests each month until fully vested on the fourth anniversary, subject to continuous service.

How is the option held according to the filing?

The option is reported as direct beneficial ownership by the reporting person, with 52,269 derivative securities beneficially owned following the transaction.

Who signed the Form 4 and when?

The filing was signed by Aaron Chan, Attorney-in-Fact on behalf of the reporting person on 08/28/2025.

What is the ticker and issuer named in the filing?

The filing lists the issuer as BridgeBio Oncology Therapeutics, Inc. with ticker BBOT.